CytoMed Therapeutics Limited (GDTC)
Nasdaq · Healthcare · Biotechnology
$1.01+9.78%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $12.1M
- 52-week range
- $0.68 – $3.68
- 52-week change
- −57.41%
- EPS (trailing)
- −$0.23
About CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury.
Headquarters: Singapore, Singapore · 42 employees · w2.cytomed.sg